These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 23703688)

  • 21. Loss of varicella zoster virus antibodies despite detectable cell mediated immunity after vaccination.
    Ludwig B; Kraus FB; Allwinn R; Keim S; Doerr HW; Buxbaum S
    Infection; 2006 Aug; 34(4):222-6. PubMed ID: 16896582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals.
    Okamoto S; Hata A; Sadaoka K; Yamanishi K; Mori Y
    J Infect Dis; 2009 Nov; 200(10):1606-10. PubMed ID: 19821719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells.
    Levin MJ; Gershon AA; Weinberg A; Song LY; Fentin T; Nowak B;
    J Infect Dis; 2006 Jul; 194(2):247-55. PubMed ID: 16779732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Augmenting immune responses to varicella zoster virus in older adults: a randomized, controlled trial of Tai Chi.
    Irwin MR; Olmstead R; Oxman MN
    J Am Geriatr Soc; 2007 Apr; 55(4):511-7. PubMed ID: 17397428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Varicella vaccination in HIV-1-infected children after immune reconstitution.
    Bekker V; Westerlaken GH; Scherpbier H; Alders S; Zaaijer H; van Baarle D; Kuijpers T
    AIDS; 2006 Nov; 20(18):2321-9. PubMed ID: 17117018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
    Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measurement of cell-mediated immunity with a Varicella-Zoster Virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization.
    Smith JG; Levin M; Vessey R; Chan IS; Hayward AR; Liu X; Kaufhold RM; Clair J; Chalikonda I; Chan C; Bernard M; Wang WW; Keller P; Caulfield MJ
    J Med Virol; 2003; 70 Suppl 1():S38-41. PubMed ID: 12627485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Varicella immunity in vaccinated healthcare workers.
    Behrman A; Lopez AS; Chaves SS; Watson BM; Schmid DS
    J Clin Virol; 2013 Jun; 57(2):109-14. PubMed ID: 23434396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
    Kim JW; Min CK; Mun YC; Park Y; Kim BS; Nam SH; Koh Y; Kwon JH; Choe PG; Park WB; Kim I
    J Clin Virol; 2015 Dec; 73():64-69. PubMed ID: 26546878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
    Ricklin ME; Lorscheider J; Waschbisch A; Paroz C; Mehta SK; Pierson DL; Kuhle J; Fischer-Barnicol B; Sprenger T; Lindberg RL; Kappos L; Derfuss T
    Neurology; 2013 Jul; 81(2):174-81. PubMed ID: 23700335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells.
    French M; Keane N; McKinnon E; Phung S; Price P
    HIV Med; 2007 Apr; 8(3):148-55. PubMed ID: 17461858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.
    Vermeulen JN; Lange JM; Tyring SK; Peters PH; Nunez M; Poland G; Levin MJ; Freeman C; Chalikonda I; Li J; Smith JG; Caulfield MJ; Stek JE; Chan IS; Vessey R; Schödel FP; Annunziato PW; Schlienger K; Silber JL
    Vaccine; 2012 Jan; 30(5):904-10. PubMed ID: 22154769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variability and gender differences in memory T cell immunity to varicella-zoster virus in healthy adults.
    Klein NP; Holmes TH; Sharp MA; Heineman TC; Schleiss MR; Bernstein DI; Kemble G; Arvin AM; Dekker CL
    Vaccine; 2006 Aug; 24(33-34):5913-8. PubMed ID: 16759768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune senescence and vaccines to prevent herpes zoster in older persons.
    Levin MJ
    Curr Opin Immunol; 2012 Aug; 24(4):494-500. PubMed ID: 22857823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do HIV-positive adult immigrants need to be screened for measles-mumps-rubella and varicella zoster virus immunization?
    Llenas-García J; Rubio R; Hernando A; Arrazola P; Pulido F
    AIDS Care; 2013 Aug; 25(8):980-9. PubMed ID: 23244745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An interferon-gamma (IFN-gamma) based whole blood assay to detect T cell response to antigens in HIV-1 infected patients.
    Benyoucef S; Hober D; De Groote D; De La Tribonniere X; Vilain V; Lion G; Bouzidi A; Wattre P
    Pathol Biol (Paris); 1997 May; 45(5):400-3. PubMed ID: 9296092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention and treatment of VZV infections in patients with HIV.
    Gershon AA
    Herpes; 2001 Jul; 8(2):32-6. PubMed ID: 11867015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults.
    Mullane KM; Winston DJ; Wertheim MS; Betts RF; Poretz DM; Camacho LH; Pergam SA; Mullane MR; Stek JE; Sterling TM; Zhao Y; Manoff SB; Annunziato PW
    J Infect Dis; 2013 Nov; 208(9):1375-85. PubMed ID: 23908479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Varicella-zoster virus immunity in dermatological patients on systemic immunosuppressant treatment.
    Hackett CB; Wall D; Fitzgerald SF; Rogers S; Kirby B
    Br J Dermatol; 2011 Jun; 164(6):1387-9. PubMed ID: 21410679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zoster vaccine: current status and future prospects.
    Oxman MN
    Clin Infect Dis; 2010 Jul; 51(2):197-213. PubMed ID: 20550454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.